Dual neutralization of both IL-17A and IL-17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded placebo-controlled phase 2b trial
Journal of the American Academy of Dermatology | Apr 05, 2018
Most read this week